Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Kairos Pharma, Ltd. Common Stock (NY:KAPA)

1.210 +0.050 (+4.31%)
Streaming Delayed Price Updated: 10:09 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 188,033
Open 1.200
Bid (Size) 1.200 (50)
Ask (Size) 1.210 (3)
Prev. Close 1.160
Today's Range 1.170 - 1.218
52wk Range 0.4000 - 3.250
Shares Outstanding 20,743,765
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Via Investor Brand Network
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
From Kairos Pharma, Ltd
Via Business Wire

Performance

YTD
-20.9%
-20.9%
1 Month
-0.8%
-0.8%
3 Month
+19.8%
+19.8%
6 Month
+32.7%
+32.7%
1 Year
-19.3%
-19.3%

More News

Read More
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
From Kairos Pharma, Ltd
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Top movers in Friday's session
Via Chartmill
Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Here are the top movers in Thursday's session.
Via Chartmill
Traders are paying attention to the gapping stocks in Thursday's session.
Via Chartmill
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV105 in Prostate Cancer
Via Investor Brand Network
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Host KOL Event on Phase 2 ENV105 Prostate Cancer Trial
Via Investor Brand Network
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Initial Phase 1 Data of ENV105 at World Lung Cancer Conference
Via Investor Brand Network
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
From Kairos Pharma, Ltd
Via Business Wire
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Kairos Pharma, Ltd
Via Business Wire
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
From Kairos Pharma, Ltd
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Frequently Asked Questions

Is Kairos Pharma, Ltd. Common Stock publicly traded?
Yes, Kairos Pharma, Ltd. Common Stock is publicly traded.
What exchange does Kairos Pharma, Ltd. Common Stock trade on?
Kairos Pharma, Ltd. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Kairos Pharma, Ltd. Common Stock?
The ticker symbol for Kairos Pharma, Ltd. Common Stock is KAPA on the New York Stock Exchange
What is the current price of Kairos Pharma, Ltd. Common Stock?
The current price of Kairos Pharma, Ltd. Common Stock is 1.210
When was Kairos Pharma, Ltd. Common Stock last traded?
The last trade of Kairos Pharma, Ltd. Common Stock was at 10/20/25 10:09 AM ET
What is the market capitalization of Kairos Pharma, Ltd. Common Stock?
The market capitalization of Kairos Pharma, Ltd. Common Stock is 25.10M
How many shares of Kairos Pharma, Ltd. Common Stock are outstanding?
Kairos Pharma, Ltd. Common Stock has 25M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.